Literature DB >> 6236260

Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells.

S W Brostoff, D W Mason.   

Abstract

Monoclonal antibody W3/25, which recognizes rat T helper cells, was injected i.p. or i.v. into Lewis rats with clinical signs of experimental allergic encephalomyelitis (EAE). This treatment, which was given 12 or 13 days after inducing EAE by the injection of purified myelin basic protein, significantly affected the course of the disease in that treated animals recovered, on the average, in 2 days, whereas control animals exhibited signs of EAE for a minimum of 4 days. Two pan-T cell monoclonal antibodies given in similar dosage failed to affect the course of the disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6236260

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Preventive effects of early anti-CD4 or anti-CD8 treatment on Borna disease in rats.

Authors:  L Stitz; M Sobbe; T Bilzer
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

Review 2.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 3.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.

Authors:  D E Smilek; D C Wraith; S Hodgkinson; S Dwivedy; L Steinman; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

5.  Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.

Authors:  Cassandra E Smith; Stephen D Miller
Journal:  J Autoimmun       Date:  2006-12       Impact factor: 7.094

Review 6.  Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis.

Authors:  Xu Zhang; Raymond Hupperts; Marc De Baets
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis.

Authors:  Hong Zhang; Joseph R Podojil; Xunrong Luo; Stephen D Miller
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

8.  Inhibition of murine nephritogenic effector T cells by a clone-specific suppressor factor.

Authors:  C M Meyers; C J Kelly
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.

Authors:  D M Karussis; U Vourka-Karussis; D Lehmann; H Ovadia; R Mizrachi-Koll; A Ben-Nun; O Abramsky; S Slavin
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees.

Authors:  M Jonker; W Slingerland; G Treacy; P van Eerd; K Y Pak; E Wilson; S Tam; K Bakker; A F Lobuglio; P Rieber
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.